New Easier-to-Use GLP-1 Pill Safe for the Heart, Study Says
In a late-stage trial, the once-daily pill met cardiovascular safety criteria and showed a lower risk of major events than placebo, Eli Lilly said.
- Eli Lilly announced today that their oral diabetes pill, orforglipron, demonstrated cardiovascular safety in a multi-year trial. The study results, presented recently at a medical meeting in Milan, indicate the medication is a viable treatment option for high-risk patients.
- The ACHIEVE-4 trial randomized participants across 6 countries to evaluate the drug's efficacy. This phase III study compared the oral treatment against injectable medication, involving 2,749 individuals over a median of 2 years.
- Meaningful improvements across two primary cardiovascular risk factors were observed, including significant reductions in major adverse cardiovascular events. The trial confirmed that the therapy met noninferiority criteria regarding these critical heart-related outcomes over the study period.
- Physicians may change how they approach type 2 diabetes treatment using this once-daily oral option to help patients manage weight. Experts believe these findings support the therapy as a convenient choice with established protection for these patients.
- Ongoing research by the company continues to evaluate the product's potential for other weight-related conditions and long-term health. Management is currently conducting additional trials to determine if broader clinical benefits exist for various patient populations globally.
35 Articles
35 Articles
Daily pill could offer alternative to insulin injections for diabetes patients at cardiovascular risk
New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, and published in The Lancet shows that, for people with type 2 diabetes at increased cardiovascular risk, a daily orforglipron pill had cardiovascular safety comparable to daily insulin glargine injections while providing greater improvements in weight and blood sugar control. However, gastrointestinal (GI) adverse events were more common with orforglipron, leading to more treatment discontinuations. The study was sponsored by Eli Lilly, the manufacturer of orforglipron.
New Easier-to-Use GLP-1 Pill Safe for the Heart, Study Says
(MedPage Today) -- Orforglipron (Foundayo) was able to claim cardiovascular safety based on the ACHIEVE-4 trial, though heart benefits remain unproven. Among adults with type 2 diabetes and obesity or overweight at risk for increased cardiovascular...
LoudounTimes.com
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine
Daily Diabetes Pill Beats Insulin on Weight and Blood Sugar
A once-daily diabetes pill called orforglipron controlled blood sugar and reduced body weight more than long-acting insulin in a large study of people at high risk of heart problems. Importantly, researchers found no evidence that the pill carried greater cardiovascular risk than insulin glargine. Orforglipron belongs to the GLP-1 family of medicines, which can help […]
Sassuolo 2000
Il Quotidiano del SudSESTO FIORENTINO (ITALPRESS) • Eli Lilly and Company, the company producing tyrzepatide, announced the results of the post-hoc analyses of the ATTAIN-1 study, according to which orforglipron was associated with significant reductions in the risk predicted at 10 years of type 2 diabetes and cardiovascular diseases in adults with obesity or overweight and at least [...]
Coverage Details
Bias Distribution
- 69% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
